Business / Corporate Aug 14, 2015
Takeda's $2.37 billion U.S. drug accord endangered after too few claimants sign up
Takeda Pharmaceutical Co.'s $2.37 billion settlement of thousands of lawsuits over its Actos diabetes medicine did not attract enough takers ahead of a deadline, raising doubts about whether the deal will survive. Asia's largest drugmaker is obligated to fund the deal after 95 percent of ...
